Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the bodyâs own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. It utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platformâs capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.

Employees

225

Sector

Biotechnology & Medical Research

Calendar

02-18 - Q4 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
12/12/25	89.68 $	+2.13%	1,863,836
11/12/25	87.81 $	-2.31%	1,398,467
10/12/25	89.89 $	+3.46%	4,459,975
09/12/25	86.88 $	-7.87%	2,339,154
08/12/25	94.30 $	+41.55%	7,495,487

Delayed Quote Nasdaq, December 12, 2025 at 09:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

89.68USD

Average target price

112.33USD

Spread / Average Target

+25.26%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 21:00:00 12/12/2025 GMT			5-day change	1st Jan Change
89.68 ^USD	+2.13%		+34.61%	+122.92%

12-11	Kymera Therapeutics Says KT-621 Receives FDA Fast Track Designation in Atopic Dermatitis	MT
12-11	Kymera Therapeutics announces U.S. FDA fast track designation for KT-621, a first-in-class, oral STAT6 degrader for the treatment of atopic dermatitis	RE

Capitalization	7.17B 6.11B 5.71B 5.37B 9.89B 650B 10.8B 66.64B 25.85B 306B 26.92B 26.35B 1,118B	P/E ratio 2025 *	-25.7x	P/E ratio 2026 *	-24.3x
Enterprise value	6.31B 5.37B 5.02B 4.72B 8.69B 571B 9.5B 58.58B 22.72B 269B 23.67B 23.17B 982B	EV / Sales 2025 *	118x	EV / Sales 2026 *	135x
Free-Float	98.65%	Yield 2025 *	-	Yield 2026 *	-

12-11	Kymera Therapeutics Says KT-621 Receives FDA Fast Track Designation in Atopic Dermatitis	MT
12-11	Kymera Therapeutics announces U.S. FDA fast track designation for KT-621, a first-in-class, oral STAT6 degrader for the treatment of atopic dermatitis	RE
12-11	Mizuho Raises Price Target on Kymera Therapeutics to $120 From $81, Keeps Outperform Rating	MT
12-11	The U.S. Food and Drug Administration Has Granted Fast Track Designation to Kt-621, Its First-In-Class, Oral Stat6 Degrader	CI
12-10	Kymera Therapeutics Prices $602 Million Common Share Offering	MT
12-10	Kymera Therapeutics announces pricing of upsized $602 million public offering at $86 per share	RE
12-09	Oppenheimer Adjusts Kymera Therapeutics PT to $120 From $67, Maintains Outperform Rating	MT
12-09	Truist Securities Adjusts Kymera Therapeutics PT to $116 From $80, Maintains Buy Rating	MT
12-09	Morgan Stanley Raises Price Target on Kymera Therapeutics to $127 From $73, Keeps Overweight Rating	MT
12-09	Kymera Therapeutics Insider Sold Shares Worth $8,917,000, According to a Recent SEC Filing	MT
12-09	Kymera Therapeutics Insider Sold Shares Worth $4,371,833, According to a Recent SEC Filing	MT
12-08	Kymera Therapeutics Launches Public Offering of Common Shares	MT
12-08	Kymera Therapeutics, Inc. - Special Call

12-11	Mizuho Raises Price Target on Kymera Therapeutics to $120 From $81, Keeps Outperform Rating	MT
12-09	Oppenheimer Adjusts Kymera Therapeutics PT to $120 From $67, Maintains Outperform Rating	MT
12-09	Truist Securities Adjusts Kymera Therapeutics PT to $116 From $80, Maintains Buy Rating	MT
12-09	Morgan Stanley Raises Price Target on Kymera Therapeutics to $127 From $73, Keeps Overweight Rating	MT
11-25	Truist Securities Raises Price Target on Kymera Therapeutics to $80 From $68, Maintains Buy Rating	MT

Kymera Therapeutics, Inc. Share Price

Equities

KYMR

US5015751044

Biotechnology & Medical Research

Valuation: Kymera Therapeutics, Inc.

Chart: Kymera Therapeutics, Inc.

Latest news: Kymera Therapeutics, Inc.

Last Transcript: Kymera Therapeutics, Inc.

Analysts' recommendations: Kymera Therapeutics, Inc.

Press Releases: Kymera Therapeutics, Inc.

News in other languages: Kymera Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Kymera Therapeutics, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

12-11	Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares	AQ
12-11	Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis	AQ
12-10	Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering	AQ
12-08	Kymera Therapeutics Announces Proposed Public Offering	AQ
12-08	Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025	AQ

12-08	MÄRKTE USA/Anleger halten sich vor Zinsentscheid mit Käufen zurück
12-08	Voorzichtige weekstart op Wall Street
12-08	MÄRKTE USA/Vor Zinsentscheid macht sich Vorsicht breit
09/07/24	MÄRKTE USA/Erneute Rekorde - Powell-Aussagen setzen keinen Impuls
09/07/24	MÄRKTE USA/Rekordjagd geht weiter - Powell-Aussagen ohne Einfluss

1 day	+2.13%
1 week	+34.61%
Current month	+32.12%
1 month	+40.94%
3 months	+90.85%
6 months	+90.97%
Current year	+122.92%

1 week	85	103
1 month	62.91	103
Current year	19.44	103
1 year	19.44	103
3 years	9.6	103
5 years	9.6	103
10 years	9.6	103

Manager	Title	Age	Since
Nello Mainolfi CEO	Chief Executive Officer	46	31/10/2019
Bruce Jacobs DFI	Director of Finance/CFO	55	14/07/2019
Jeremy Chadwick COO	Chief Operating Officer	62	21/05/2023

Director	Title	Age	Since
Bruce Booth CHM	Chairman	50	31/07/2017
Nello Mainolfi BRD	Director/Board Member	46	31/10/2019
Gorjan Hrustanovic BRD	Director/Board Member	36	29/02/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
KYMERA THERAPEUTICS, INC.	+2.13%	+34.61%	+112.86%	+246.92%	7.17B
LONZA GROUP AG	-1.79%	-5.23%	-3.38%	+8.38%	45.43B
IQVIA HOLDINGS INC.	-1.65%	-1.59%	+11.65%	+2.52%	37.85B
BEONE MEDICINES AG	-0.55%	-1.19%	+77.90%	+53.34%	35.31B
CELLTRION, INC.	+0.05%	+1.91%	+5.47%	+18.52%	27.66B
MEDPACE HOLDINGS, INC.	-1.46%	+1.78%	+61.28%	+159.86%	15.72B
REVOLUTION MEDICINES, INC.	+0.52%	-0.90%	+75.34%	+238.71%	15.26B
ICON PUBLIC LIMITED COMPANY	-1.76%	+0.38%	-10.36%	-5.89%	14.25B
ASCENDIS PHARMA A/S	+4.88%	+7.29%	+69.72%	+79.48%	13.47B
IONIS PHARMACEUTICALS, INC.	+2.12%	-1.05%	+120.76%	+111.96%	13.09B
Average	+0.25%	+3.39%	+52.12%	+91.38%	22.52B
Weighted average by Cap.	-0.41%	+0.04%	+37.67%	+58.83%

	2025 *	2026 *
Net sales	53.36M 45.46M 42.46M 39.95M 73.55M 4.83B 80.35M 496M 192M 2.28B 200M 196M 8.31B	47.38M 40.36M 37.7M 35.48M 65.31M 4.29B 71.35M 440M 171M 2.02B 178M 174M 7.38B
Net income	-295M -251M -235M -221M -407M -26.73B -444M -2.74B -1.06B -12.6B -1.11B -1.08B -45.97B	-338M -288M -269M -253M -465M -30.58B -508M -3.14B -1.22B -14.41B -1.27B -1.24B -52.59B
Net Debt	-867M -739M -690M -649M -1.2B -78.55B -1.31B -8.06B -3.12B -37.03B -3.25B -3.19B -135B	-772M -657M -614M -578M -1.06B -69.89B -1.16B -7.17B -2.78B -32.94B -2.9B -2.83B -120B